Clearside Biomedical CLSD 深 沪
等待开盘 07-30 09:30:00 美东时间
0.48
+0.035
+7.84%
华盛通- 最 高0.57
- 今 开0.425
- 成交量 357.39万股
- 最 低 0.425
- 昨 收 0.4451
- 总市值 3730.01万
- 52周最高 1.65
- 市盈率 静 --
- 换手率 4.60%
- 52周最低 0.292
- 委 比 56.58%
- 总股本 7770.85万
- 历史最高 25.08
- 量 比 0.07
- 振 幅 32.58%
- 历史最低 0.292
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
Clearside Biomedical's XIPERE, an injectable corticosteroid for treating uveitic macular edema, has received approval in the U.S., Canada, Australia, and Singapore, with regulatory reviews ongoing in China. The drug is administered via the company's proprietary suprachoroidal space (SCS) injection platform, utilizing the SCS Microinjector, which allows precise drug delivery to the back of the eye. Clearside is expanding its global presence and ad...
07-23 11:05
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 90.1% to $2.3 during...
07-19 01:06
美股大行评级 | 潜在涨幅59.98%！百度获花旗升目标价至140美元，维持"买入"评级
今日重点评级关注：花旗：维持百度"买入"评级，目标价从138美元升至140美元；Maxim Group：维持Caledonia Mining"买入"评级，目标价从21美元升至28美元
07-18 09:25
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
Clearside Biomedical, Inc. announced plans to explore strategic alternatives to maximize shareholder value, including asset sales, licensing, or collaborations. The company's SCS Microinjector platform enables non-surgical delivery of therapies to the back of the eye, with approved products in the U.S., Singapore, and Australia. Its CLS-AX program for wet AMD achieved positive Phase 2b results and FDA alignment for a Phase 3 trial. Clearside has ...
07-17 11:05
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
Clearside Biomedical announced its suprachoroidal delivery platform and product candidates, CLS-AX and XIPERE, will be highlighted at the 2025 CTS Meeting. CLS-AX, an axitinib injectable suspension, targets retinal diseases through a novel delivery method, showing promise in early trials. partnerships with Regenxbio and Aura Biosciences expand its应用范围。Clearside's SCS Microinjector enables targeted drug delivery, potentially reducing side effects.
06-17 11:05
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
HC Wainwright & Co. Maintains Buy on Clearside Biomedical, Lowers Price Target to $5
HC Wainwright & Co. analyst Yi Chen maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target from $6 to $5.
05-23 23:45
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Needham Maintains Buy on Clearside Biomedical, Lowers Price Target to $3
Needham analyst Serge Belanger maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target from $4 to $3.
05-15 19:06
